- $1.92bn
- $1.57bn
- $125.58m
Xencor Inc expected to post a loss of 65 cents a share - Earnings Preview
Xencor rises after partnering with J&J to develop cancer drug
Brief: Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations
Xencor Inc reports results for the quarter ended in June - Earnings Summary
Brief: Xencor Reports Q2 2021 Financial Results
Xencor Inc expected to post a loss of 56 cents a share - Earnings Preview
Xencor Inc expected to post a loss of 56 cents a share - Earnings Preview
Brief: Xencor And Bristol Myers Squibb Enter License Agreement For Use Of Xtend Xmab Technology In SARS-COV-2 Neutralizing Monoclonal Antibody Combination For Treatment Of COVID-19
Xencor Inc reports results for the quarter ended in March - Earnings Summary
Brief: Xencor Reports Q1 Loss Per Share Of $0.04
Xencor Inc expected to post a loss of 67 cents a share - Earnings Preview
Brief: Xencor Doses First Subject In Phase 1 Study Of Xmab®564, An Engineered Il-2 Cytokine In Development For Autoimmune Diseases
Brief: Xencor Reports Fourth Quarter And Full Year 2020 Financial Results
Brief: Xencor Inc Reports 7.6% Passive Stake In Miragen Therapeutics
Brief: Xencor, MD Anderson Enter Strategic Collaboration To Develop Novel T Cell-Engaging Bispecific Antibodies
Brief: miRagen Enters Into License Agreement With Xencor For Use Of Xtend Antibody Technology For Investigational Antibodies To Treat Thyroid Eye Disease
Brief: Biocytogen Have Reached Agreement With Xencor, Inc., For Licensing Of Co's Fully Human Antibody Renmab/Renlite
Brief: Xencor Collaborates with Janssen to Discover Novel CD28 Bispecific Antibodies for Treatment of Prostate Cancer
Brief: Xencor, Morphosys And Incyte Enter Into Global Development Collaboration